Intestinal barrier dysfunction mediates Whipple's disease immune reconstitution inflammatory syndrome (IRIS).
Whipple's disease
barrier dysfunction
immune reconstitution inflammatory syndrome
inflammation
leaky gut
microbial translocation
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
17
03
2022
received:
07
02
2022
accepted:
30
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
30
4
2022
Statut:
ppublish
Résumé
Classical Whipple's disease (CWD) affects the gastrointestinal tract and causes chronic diarrhea, malabsorption, and barrier dysfunction with microbial translocation (MT). Immune reconstitution inflammatory syndrome (IRIS) is a serious complication during antimicrobial treatment of CWD. The pathomechanisms of IRIS have not been identified and mucosal barrier integrity has not been studied in patients with IRIS CWD. In 96 CWD patients (n = 23 IRIS, n = 73 non-IRIS) and 30 control subjects, we analysed duodenal morphology by histology, measured serum markers of MT, and proinflammatory cytokines in biopsy supernatants, and correlated microbial translocation with T cell reconstitution and activation. Before treatment, duodenal specimens from patients who later developed IRIS exhibited a more pronounced morphological transformation that suggested a disturbed barrier integrity when compared with the non-IRIS group. Villous atrophy was mediated by increased apoptosis of epithelial cells, which was insufficiently counterbalanced by regenerative proliferation of crypt cells. Pretreatment deficiencies in the mucosal secretion of proinflammatory cytokines and chemokines (e.g., IL-6, CCL2) in these patients markedly resolved after therapy induction. High serum levels of lipopolysaccharides (LPS), soluble CD14 (sCD14), and LPS-binding protein (LBP) combined with low endotoxin core antibody (EndoCAb) titres suggested systemic MT in CWD patients developing IRIS. CD4 Prolonged MT across a dysfunctional intestinal mucosal barrier due to severe tissue damage favors dysbalanced immune reconstitution and systemic immune activation in IRIS CWD. Therefore, the monitoring of inflammatory and MT markers in CWD patients might be helpful in identifying patients who are at risk of developing IRIS. Therapeutic strategies to reconstitute the mucosal barrier and control inflammation could assist in the prevention of IRIS.
Sections du résumé
BACKGROUND & AIMS
Classical Whipple's disease (CWD) affects the gastrointestinal tract and causes chronic diarrhea, malabsorption, and barrier dysfunction with microbial translocation (MT). Immune reconstitution inflammatory syndrome (IRIS) is a serious complication during antimicrobial treatment of CWD. The pathomechanisms of IRIS have not been identified and mucosal barrier integrity has not been studied in patients with IRIS CWD.
METHODS
In 96 CWD patients (n = 23 IRIS, n = 73 non-IRIS) and 30 control subjects, we analysed duodenal morphology by histology, measured serum markers of MT, and proinflammatory cytokines in biopsy supernatants, and correlated microbial translocation with T cell reconstitution and activation.
RESULTS
Before treatment, duodenal specimens from patients who later developed IRIS exhibited a more pronounced morphological transformation that suggested a disturbed barrier integrity when compared with the non-IRIS group. Villous atrophy was mediated by increased apoptosis of epithelial cells, which was insufficiently counterbalanced by regenerative proliferation of crypt cells. Pretreatment deficiencies in the mucosal secretion of proinflammatory cytokines and chemokines (e.g., IL-6, CCL2) in these patients markedly resolved after therapy induction. High serum levels of lipopolysaccharides (LPS), soluble CD14 (sCD14), and LPS-binding protein (LBP) combined with low endotoxin core antibody (EndoCAb) titres suggested systemic MT in CWD patients developing IRIS. CD4
CONCLUSION
Prolonged MT across a dysfunctional intestinal mucosal barrier due to severe tissue damage favors dysbalanced immune reconstitution and systemic immune activation in IRIS CWD. Therefore, the monitoring of inflammatory and MT markers in CWD patients might be helpful in identifying patients who are at risk of developing IRIS. Therapeutic strategies to reconstitute the mucosal barrier and control inflammation could assist in the prevention of IRIS.
Identifiants
pubmed: 35478447
doi: 10.1002/iid3.622
pmc: PMC9046915
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Lipopolysaccharide Receptors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e622Informations de copyright
© 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Inflamm Bowel Dis. 2009 Dec;15(12):1824-36
pubmed: 19637338
Nat Rev Microbiol. 2012 Jan 09;10(2):150-6
pubmed: 22230950
J Immunol. 2013 Mar 1;190(5):2354-61
pubmed: 23365082
Gut. 1998 Mar;42(3):357-61
pubmed: 9577341
Semin Thromb Hemost. 2010 Sep;36(6):575-85
pubmed: 20865634
J Endotoxin Res. 2001;7(3):167-202
pubmed: 11581570
Arch Pathol Lab Med. 2013 Sep;137(9):1262-9
pubmed: 23991739
Front Immunol. 2020 Dec 15;11:596631
pubmed: 33384690
Lancet Infect Dis. 2008 Mar;8(3):179-90
pubmed: 18291339
Infect Immun. 2015 Feb;83(2):482-91
pubmed: 25385798
Immun Inflamm Dis. 2022 May;10(5):e622
pubmed: 35478447
Eur J Immunol. 2006 Nov;36(11):3007-16
pubmed: 17039565
Internist (Berl). 2011 Sep;52(9):1038, 1040-4, 1046
pubmed: 21847579
Gastroenterology. 2010 Jan;138(1):210-20
pubmed: 19664628
J Gerontol. 1984 Nov;39(6):642-7
pubmed: 6491177
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
Mol Immunol. 2012 Jun;51(2):112-27
pubmed: 22445606
Curr Allergy Asthma Rep. 2007 Nov;7(6):436-43
pubmed: 17986374
J Immunol. 2011 Oct 15;187(8):4061-7
pubmed: 21918190
Gut. 2013 Jul;62(7):1062-71
pubmed: 22689519
J Cardiothorac Vasc Anesth. 2001 Aug;15(4):451-4
pubmed: 11505348
Mucosal Immunol. 2017 Nov;10(6):1542-1552
pubmed: 28176790
J Infect Dis. 2014 Mar 1;209(5):739-48
pubmed: 24133185
J Clin Invest. 2001 Aug;108(3):485-93
pubmed: 11489942
Blood. 2001 Dec 15;98(13):3800-8
pubmed: 11739189
Microbes Infect. 2006 Mar;8(3):946-52
pubmed: 16483818
Clin Microbiol Rev. 2013 Jan;26(1):2-18
pubmed: 23297256
Immunobiology. 2008;213(3-4):193-203
pubmed: 18406367
Inflamm Res. 2013 Sep;62(9):865-9
pubmed: 23775039
Ann Intern Med. 2010 Dec 7;153(11):710-7
pubmed: 21135294
AIDS Res Ther. 2007 Nov 30;4:29
pubmed: 18053126
Life (Basel). 2021 Jan 18;11(1):
pubmed: 33477581
Infection. 2014 Dec;42(6):951-9
pubmed: 25070877
Expert Opin Drug Saf. 2014 Mar;13(3):341-50
pubmed: 24512544
Prog Clin Biol Res. 1995;392:263-72
pubmed: 8524931
Inflamm Bowel Dis. 2007 Mar;13(3):269-77
pubmed: 17206721